Pediatrics in Review
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Pediatrics in Review. 1988;10:16-31.)
© 1988 American Academy of Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow Rapid Responses: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

Autism

In 1982, three autistic children with hyperserotoninemia were reported to have had an impressive clinical response to treatment with fenfluramine—a finding that generated considerable hope and excitement. Now, well-designed studies have evaluated both the relationship of serotonin levels to autism and the clinical and biochemical effects of fenfluramine.

Blood serotonin levels are not universally elevated in children with autism, and mean blood serotonin concentrations in autistic children are not significantly different from those in normal or in nonautistic retarded children. Treatment with fenfluramine does cause significant decreases in blood serotonin concentrations in autistic children, but such biochemical changes are not associated with changes in psychometric measurements of general intelligence.






HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Pediatrics Pediatrics in Review
Copyright © 1988 by the American Academy of Pediatrics.